
A



B




Figure 1A, B



C
Mean Fluorescence Intensity
350
300
250
200
150
100
50
0
IgG
IgM
*
D
Complement Hemolytic Activity (%)
120
100
80
60
40
20
0
Naive control
Non-Presensitized
Presensitized

Figure 1C, D



A
100
75
50
25
0
Graft survival (%)
0
25
50
75
100
Post-operative Days
untreated
C5mAb
CsA
CyP
C5mAb+CsA
C5mAb+CyP
CsA+CyP
C5mAb+CsA+CyP

Figure 2A

B




Figure 2B



Complement Hemolytic Activity (%)
120
100
80
60
40
20
0
*
naive control
untreated
CsA
CyP
CsA+CyP
C5mAb
C5mAb+CsA
C5mAb+CyP
C5mAb+CsA+CyP

Figure 3




A
Mean Fluorescence Intensity
350
300
250
200
150
100
50
0
IgG
IgM
*
Naïve control
untreated
CsA
CyP
C5mAb
C5mAb +CsA
C5mAb +CyP
CsA+CyP
C5mAb +CsA+CyP
B
Mean Fluorescence Intensity
120
100
80
60
40
20
0
IgG
IgM
0
20
40
60
80
100
Post-operative Days

Figure 4A, B

C



D




Figure 4C, D



70
60
50
40
30
20
10
0
Mean Fluorescence Intensity
IgG2a
IgG2b
*
**
Naive
Rejected
Accommodated

Figure 5



naive
untreated
POD3
C5mAb+CsA+CyP
POD12
POD100
Bcl-2
Calsequestrin
Bcl-xl
Calsequestrin

Figure 6




A
Naive heart
Second naive heart
Rejection
Naive C3H
Presensitized BALB/c with accommodating first heart
B
Accommodated heart
Accommodated heart
Rejection
Presensitized BALB/c with accommodating heart
Presensitized BALB/c treated with CsA+CyP
C
Accommodated heart
Second accommodated heart
Acceptance
Presensitized BALB/c with accommodating heart
Presensitized BALB/c with accommodating first heart

Figure 7 A, B, C

A



B




Figure 8A, B




Figure 9A, B



Mean Fluorescence Intensity
200
180
160
140
120
100
80
60
40
20
0
0
2
4
6
8
10
12
14
Days after skin presensitization
IgG
IgM

Figure 10A



B
Presensitized
Non-presensitized
HE
IgG
C3
C5
Mac-1
a
b
c
d
e
f
g
h
i
j

Figure 10B




C
500
400
300
200
100
0
IgG
IgM
*
Mean Fluorescence Intensity
D
140
120
100
80
60
40
20
0
Complement Hemolytic Activity (%)
Naive
Non-presensitized
Presensitized

Figure 10C, D


A
Graft survival (%)
100
75
50
25
0
0
25
50
75
100
Post-operative Days
untreated
CsA
anti-C5mAb
LF
anti-C5mAb+CsA
anti-C5mAb+LF
CsA+LF
anti-C5mAb+CsA+LF *



B
Serum Creatinine Levels (µmol/L)
400
300
200
100
0
Naive
untreated
CsA
Anti-C5
LF
Anti-C5 +CsA
Anti-C5 +LF
CsA+LF
Anti-C5 +CsA+LF
*

Figure 11A, B

C




Figure 11 C



Complement Hemolytic Activity (%)
140
120
100
80
60
40
20
0
*
naive
untreated
CsA
LF
CsA+LF
Anti-C5
Anti-C5+CsA
Anti-C5+LF
Anti-C5+CsA+LF
Anti-C5+CsA+LF
Anti-C5+CsA+LF
D7
D60
D100

Figure 12



A
Mean Fluorescence Intensity
500
400
300
200
100
0
IgG
IgM
**
*
Naive
untreated
CsA
Anti-C5
LF
Anti-C5 +CsA
Anti-C5 +LF
CsA+LF
Anti-C5 +CsA+LF
B
Mean Fluorescence Intensity
500
400
300
200
100
0
IgG1
IgG2a
IgG2b
IgG3
*
**
Naive
Untreated
Anti-C5 +CsA+LF

Figure 13 A, B



Naive
Untreated
POD7
Anti-C5+CsA+LF
POD11
POD100
Bcl-2
β-actin
Bcl-xl
β-actin

Figure 14